A CNS CRO is a research organization that focuses on neurological diseases. These companies provide a variety of services including animal models and cell-based models, pre-clinical evaluation of test compounds, and behavioral and cognitive assessment. They also provide expertise in the area of neurodegenerative disease. Choosing a CNS CRO is crucial to the success of any research project.
Vial CRO
Vial CRO is an integrated product development company based in Australia and New Zealand that specializes in Phase I and II clinical trials. The company has a strong reputation in this industry and its global presence enables it to offer a broad range of services to pharmaceutical and biotech clients. With offices in the UK and the US, the company can help clients across the globe with a range of services, including regulatory affairs.
As the company's Principal Consultant, Natalie Thomas provides strategic regulatory, non-clinical, and clinical development advice to the company's clients. She is a member of the Editorial Board of the Journal of Regulatory Rapporteur and has over ten years' experience in the pharmaceutical industry. She joined Vial CRO in 2014 after working at a number of other firms.
Precision
Precision in CNS CRO has a dedicated team of experienced clinical research professionals that deliver full-service global CNS clinical trials. This team includes experts who specialize in biomarker-driven clinical development. They can help companies design and execute clinical trials to determine which therapies are best for patients. Precision can also assist clients with biomarker discovery and validation.
Precision for Medicine has pioneered the use of biomarkers in clinical research. This innovative approach to research and development has already made a positive impact on patient lives. It is a promising field with great potential for the future of medicine. It involves biomarkers, genomics testing, and companion diagnostics. The development of therapeutics based on these markers provides a clear pathway for translational medicine success. It is essential for companies to work with a patient-centric CRO that understands the value of biomarker-driven research.
Neuroservices-Alliance
Neuroservices-Alliance is a global CRO consortium that specializes in neuro-pharmacology and pain research. It offers flexible study plans, short turnaround times, and pharmacological assays based on electrophysiological recordings. The consortium also offers services that assist early-stage R&D programs.
The growing number of neurological disorders and increasing focus on research have driven the growth of the neurology CRO industry. For example, the Parkinson's Foundation's Prevalence Project estimates that more than one million Americans will have Parkinson's by 2030. The increase in neurological-related clinical trials will also influence the growth of the neurology CRO market.
Nasson Science
Nasson Science CNS CRO has over 25 years of experience in developing new CNS drugs and is based in Osong, Korea. The company has a global level laboratory animal center and is actively leading pre-clinical efficacy evaluation efforts in the CNS field. The company is also expanding into other disease areas, including partial pain, autoimmune-related diseases, and cancer.
The company began operations with three staff members and plans to have 25 employees by 2020. The company has already made a profit and is growing its staff. It plans to add another twenty to thirty employees this year, and will construct its own animal model facility and expand its laboratory. Its sales are projected to grow from 1.7 billion won last year to over four billion won the following year, and Nasson Science plans to go public within two years.
CenExel Clinical Research
CenExel Clinical Research, based in Salt Lake City, Utah, is a company that provides medical support for clinical trials. It recently acquired California Neuroscience Research, a clinical research facility in Los Angeles. The firm has over two decades of experience in neurological and psychiatric studies. Its primary indications are Alzheimer's disease, anxiety, migraine pain, and depression.
CenExel's clinical research network is composed of 13 centers across the United States. These centers specialize in Neurology, Pain, Psychiatry, Vaccines, and dermatology. Its mission is to accelerate the development and registration of innovative therapies.
